cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours

Journal of Clinical Pathology

Volumn 59, Issue 2, 2006, Pages 160-165

  Karube, K ^a,b   Nabeshima, K ^a   Ishiguro, M ^a   Harada, M ^b   Iwasaki, H ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; COLLAGEN TYPE 6; COLLAGEN TYPE 7; COMPLEMENTARY DNA; KERATIN; SOMATOMEDIN BINDING PROTEIN 6; SURVIVIN; TENASCIN;

ADULT; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; PERIPHERAL NERVE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NERVE SHEATH NEOPLASMS; NEURILEMMOMA; NEUROFIBROMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TENASCIN; UP-REGULATION;

EID: 32544437208     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.023598     Document Type: Article

References (38)

1. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57:2006-21.
2. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990;62:187-92.
3. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990;249:181-6.
4. Daston MM, Scrable H, Nordlund M, et al. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 1992;8:415-28.
5. Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol 2003;21:4586-91.
6. Woodruff JM, Kourea HP, Louis DN, et al. Malignant peripheral nerve sheath tumour (MPNST). In: Kleihues P, Cavenee WK, eds. Tumours of the nervous system. Lyon, France: IARC Press, 2000:172-4.
7. Ohshima K, Karube K, Hamasaki M, et al. Imbalances of chemokines, chemokine receptors and cytokines in Hodgkin lymphoma: classical Hodgkin lymphoma vs. Hodgkin-like ATLL. Int J Cancer 2003;106:706-12.
8. Fujii A, Ohshima K, Hamasaki M, et al. Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma. Int J Oncol 2004;24:529-38.
9. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 2002;197:388-94.
10. Ryan B, ÒDonovan N, Browne B, et al. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 2005;92:120-4.
11. Kaarteenaho-Wiik R, Soini Y, Pollanen R, et al. Over-expression of tenascin-C in malignant pleural mesothelioma. Histopathology 2003;42:280-91.
12. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-42.
13. Reed JC. The survivin saga goes in vivo. J Clin Invest 2001;108:965-9.
14. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4.
15. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999;1:461-0.
16. Jaskoll T, Chen H, Min Zhou Y, et al. Developmental expression of survivin during embryonic submandibular salivary gland development. BMC Dev Biol 2001;1:5.
17. Stilgenbauer S, Schaffner C, Winkler D, et al. The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol 2000;11:127-30.
18. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4.
19. Islam A, Kageyama H, Takada N, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-23.
20. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542-7.
21. Ikeguchi M, Ueda T, Sakatani T, et al. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002;11:33-40.
22. Chiquet-Ehrismann R. Tenascins, a growing family of extracellular matrix proteins. Experientia 1995;51:853-62.
23. Borsi L, Carnemolla B, Ponassi M, et al. Steady-state levels of different tenascin mRNAs in various normal human tissues. Cell Biol Int 1993;17:325-9.
24. Koukoulis GK, Gould VE, Bhattacharyya A, et al. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol 1991;22:636-43.
25. Aishima S, Taguchi K, Terashi T, et al. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Mod Pathol 2003;16:1019-27.
26. Kaarteenaho-Wiik R, Soini Y, Pollanen R, et al. Over-expression of tenascin-C in malignant pleural mesothelioma. Histopathology 2003;42:280.
27. Reardon D, Akabani A, Coleman G, et al. Phase II trial of murine (131 )I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389-97.
28. Goetz C, Riva P, Poepperl G, et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 2003;62:321-8.
29. Schaller G, Fuchs I, Pritze W, et al. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996;2:1879-85.
30. Robbins P, Papadimitriou J. Glandular peripheral nerve sheath tumours. Pathol Res Pract 1994;190:412-15.
31. Burchardt ER, Hein R, Bosserhoff AK. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin Exp Dermatol 2003;28:515-20.
32. Pavelic K, Kolak T, Kapitanovic S, et al. Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol 2003;201:430-8.
33. El-Badry OM, Helman U, Chatten J, et al. Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest 1991;87:648-57.
34. Singleton JR, Randolph AE, Feldman EL. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res 1996;56:4522-9.
35. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Physiol 1993;55:131-53.
36. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
37. Roghani M, Segovia B, Whitechurch O, et al. Purification from human cerebrospinal fluid of insulin-like growth factor binding proteins (IGFBPs). Isolation of IGFBP-2, an altered form of IGFBP-3 and a new IGFBP species. Growth Regul 1991;1:125-30.
38. Chambery D, De Galle B, Ehrenborg E, et al. Multi-hormonal regulation of IGFBP-6 expression in human neuroblastoma cells. Growth Horm IGF Res 2000;10:349-59.